ZM-241,385

ZM-241,385
Names
	Preferred IUPAC name 4-(2-{[7-Amino-2-(furan-2-yl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino}ethyl)phenol
Identifiers
CAS Number	139180-30-6 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL113142 ;
ChemSpider	153646 ;
ECHA InfoCard	100.216.533
IUPHAR/BPS	405;
PubChem CID	176407;
UNII	5NIC36BO71 ;
CompTox Dashboard (EPA)	DTXSID80160954 ;
	InChI InChI=1S/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22) Key: PWTBZOIUWZOPFT-UHFFFAOYSA-N ; InChI=1/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22) Key: PWTBZOIUWZOPFT-UHFFFAOYAJ;
	SMILES Oc1ccc(CCNc2nc3nc(c4ccco4)nn3c(N)n2)cc1;
Properties
Chemical formula	C16H15N7O2
Molar mass	337.343 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

ZM-241,385 is a high affinity antagonist ligand selective for the adenosine A_2A receptor.^[1]

In animal models, ZM-241,385 has been shown to protect against beta amyloid neurotoxicity and therefore may be useful as a treatment for Alzheimer's disease.^[2] ZM-241,385 has also been shown to enhance L-DOPA derived dopamine release and therefore may be useful in the treatment of Parkinson's disease.^[3]

References

^ Palmer TM, Poucher SM, Jacobson KA, Stiles GL (December 1995). "¹²⁵I-4-(2-(7-amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5) triazin-5-yl-amino)ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor". Molecular Pharmacology. 48 (6): 970–4. PMC 3479638. PMID 8848012.
^ Dall'Igna OP, Porciúncula LO, Souza DO, Cunha RA, Lara DR, Dall'lgna OP (April 2003). "Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity". British Journal of Pharmacology. 138 (7): 1207–9. doi:10.1038/sj.bjp.0705185. PMC 1573785. PMID 12711619.
^ Gołembiowska K, Dziubina A (September 2004). "Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats". Neuropharmacology. 47 (3): 414–26. doi:10.1016/j.neuropharm.2004.04.018. PMID 15275831.

ZM+241385 at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.